Breaking News Instant updates and real-time market news.

MLHR

Herman Miller

$37.95

-0.55 (-1.43%)

, KNL

Knoll

$23.14

1.1 (4.99%)

10:25
12/26/17
12/26
10:25
12/26/17
10:25

On The Fly: Top five analyst actions

Catch up on today's top five analyst rating changes with this list compiled by The Fly: 1. Raymond James analyst Budd Bugatch upgraded Herman Miller (MLHR) to Outperform following newly passed tax reform, as the analyst believes the economic backdrop favors a strong office furniture demand environment and tax reform increases incentives for office furniture purchases. 2. Bugatch also upgraded Knoll (KNL) following the enactment of U.S. tax reform, as he believes its sales force, new product offerings, competitive pricing, and recently announced Muuto acquisition position the company to drive revenue growth as macro conditions improve. 3. Janney Capital analyst Michael Gaugler upgraded Unitil (UTL) to Buy citing the stock's "compelling" valuation. 4. William Blair analyst Tim Lugo late Friday downgraded Agile Therapeutics (AGRX) to Market Perform from Outperform after the company received a complete response letter from the FDA over its hormonal contraceptive patch, Twirla. While the issues raised by the FDA may be addressable, he has concerns regarding management's execution of the company's lead product. 5. Ignyta (RXDX) was downgraded to Hold at SunTrust and to Neutral at Ladenburg after the company agreed to be acquired by Roche (RHHBY) for $27 per share. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

MLHR

Herman Miller

$37.95

-0.55 (-1.43%)

KNL

Knoll

$23.14

1.1 (4.99%)

UTL

Unitil

$45.42

1.1 (2.48%)

AGRX

Agile Therapeutics

$2.52

-2.24 (-47.06%)

RXDX

Ignyta

$26.85

11.3 (72.67%)

RHHBY

Roche

$31.13

0.07 (0.23%)

  • 26

    Dec

  • 23

    Feb

MLHR Herman Miller
$37.95

-0.55 (-1.43%)

12/26/17
RAJA
12/26/17
UPGRADE
Target $43
RAJA
Outperform
Herman Miller upgraded to Outperform from Market Perform at Raymond James
Raymond James analyst Budd Bugatch upgraded Herman Miller to Outperform and established a $43 price target following newly passed tax reform. The analyst believes the economic backdrop favors a strong office furniture demand environment and tax reform increases incentives for office furniture purchases given immediate expensing of short-term capital assets.
06/27/17
SIDC
06/27/17
INITIATION
Target $38
SIDC
Buy
Herman Miller initiated with a Buy at Sidoti
Sidoti analyst Gregory Burns started Herman Miller with a Buy rating and $38 price target.
03/23/17
03/23/17
UPGRADE

Market Perform
Herman Miller upgraded to Market Perform from Underperform at Raymond James
As previously reported, Raymond James upgraded Herman Miller to Market Perform from Underperform. Analyst Budd Bugatch views risk/reward a more balanced following the Q3 report.
03/23/17
RAJA
03/23/17
UPGRADE
RAJA
Market Perform
Herman Miller upgraded to Market Perform from Underperform at Raymond James
KNL Knoll
$23.14

1.1 (4.99%)

08/16/17
SIDC
08/16/17
INITIATION
SIDC
Buy
Knoll initiated with a Buy at Sidoti
Sidoti initiated Knoll with a Buy and a $28 price target.
12/26/17
RAJA
12/26/17
UPGRADE
Target $26
RAJA
Strong Buy
Knoll upgraded to Strong Buy from Outperform at Raymond James
Raymond James analyst Budd Bugatch upgraded Knoll and raised its price target to $26 from $23 following the enactment of US tax reform. The analyst believes Knoll's sales force, new product offerings, competitive pricing, and recently announced Muuto acquisition position the company to drive revenue growth as macro conditions improve.
08/28/17
08/28/17
UPGRADE

Outperform
Knoll upgraded to Outperform at Raymond James
As previously reported, Raymond James upgraded Knoll to Outperform from Market Perform and established a $20 price target. Analyst Budd Bugatch views valuation as attractive and said Knoll is well positioned to drive revenue growth as the macro environment for office furniture normalizes given an increased sales force, new product offerings, and competitive pricing.
08/28/17
RAJA
08/28/17
UPGRADE
RAJA
Outperform
Knoll upgraded to Outperform from Market Perform at Raymond James
UTL Unitil
$45.42

1.1 (2.48%)

12/18/17
BOFA
12/18/17
INITIATION
Target $49
BOFA
Neutral
Unitil initiated with a Neutral at BofA/Merrill
BofA/Merrill analyst Julien Dumoulin- initiated Unitil Corp. with a Neutral and $49 price target saying consensus estimates are too high and expects growth to be more in line with current ratebase trends.
12/26/17
JANY
12/26/17
UPGRADE
Target $50
JANY
Buy
Unitil upgraded to Buy from Neutral at Janney Capital
Janney Capital analyst Michael Gaugler upgraded Unitil to Buy citing "compelling" valuation and lowered its price target to $50 from $52.
AGRX Agile Therapeutics
$2.52

-2.24 (-47.06%)

12/22/17
JANY
12/22/17
DOWNGRADE
JANY
Neutral
Agile Therapeutics downgraded to Neutral from Buy at Janney Capital
12/26/17
WBLR
12/26/17
DOWNGRADE
WBLR
Market Perform
Agile Therapeutics downgraded to Market Perform at William Blair
William Blair analyst Tim Lugo late Friday downgraded Agile Therapeutics to Market Perform from Outperform after the company received a complete response letter from the FDA over its hormonal contraceptive patch, Twirla. The analyst thinks the issues raised by the FDA may be addressable but has concerns regarding management's execution of the company's lead product.
12/26/17
NEED
12/26/17
NO CHANGE
Target $14
NEED
Buy
Corium price target lowered to $14 from $16 at Needham
Needham analyst Serge Belanger lowered his price target on Corium (CORI) to $14 after the FDA's letter on the Twirla contraceptive patch by Agile Therapeutics (AGRX) outlined its deficiencies. Belanger says Twirla was Corium's most near-term revenue opportunity, pushing out its anticipated approval by about 12 months. The analyst keeps his Buy rating on Corium.
12/26/17
JEFF
12/26/17
NO CHANGE
Target $13
JEFF
Buy
Corium's partner's CRL looks addressable, says Jefferies
Jefferies analyst David Steinberg believes the complete repose letter received by Corium's (CORI) partner Agile Therapeutics (AGRX) appears addressable. Management indicated the issues relate to Agile's use of standard square-patch tests to assess its circular patch, Steinberg tells investors in a research note. They believe the adhesion profile is "excellent" and, importantly, data addressing the issue has not yet been reviewed by the FDA, the analyst adds. He notes that Twirla's profitability impact to Corium is relatively low, causing only a modest reduction in out-year estimates from the delayed approval. Steinberg keeps a Buy rating on Corium with a $13 price target.
RXDX Ignyta
$26.85

11.3 (72.67%)

12/22/17
JEFF
12/22/17
DOWNGRADE
Target $27
JEFF
Hold
Ignyta downgraded to Hold from Buy at Jefferies
Jefferies analyst Maury Raycroft downgraded Ignyta (RXDX) to Hold after the company reached an agreement to be acquired by Roche (RHHBY). The analyst maintains a $27 price target for shares.He expects the deal to close.
12/22/17
STFL
12/22/17
NO CHANGE
STFL
Buy
Roche deal has postive read-through for Loxo Oncology, says Stifel
Stifel analyst Stephen Willey anticipates bears will say Roche's (RHHBY) deal for Ignyta (RXDX) reflects the potential competitiveness of Ignyta's entrectinib relative to Loxo Oncology's (LOXO) larotrectinib in malignancies caused by NTRK fusions. However, he is "firmly" in the bull camp that Roche's acquisition was primarily focused around the opportunity for entrectinib in treating ROS-1 fusions in NSCLC and that this deal reflects big pharma's appetite for targeted agents and long-duration oncology assets. Willey has a Buy rating on Loxo shares.
12/26/17
LTCO
12/26/17
DOWNGRADE
LTCO
Neutral
Ignyta downgraded to Neutral from Buy at Ladenburg
Ladenburg Thalmann analyst Kevin Degeeter downgraded Ignyta (RXDX) to Neutral after the company agreed to be acquired by Roche (RHHBY) for $27 per share.
12/26/17
RHCO
12/26/17
DOWNGRADE
RHCO
Hold
Ignyta downgraded to Hold from Buy at SunTrust
SunTrust downgraded Ignyta (RXDX) to Hold after the company agreed to be acquired by Roche (RHHBY) for $27 per share.
RHHBY Roche
$31.13

0.07 (0.23%)

12/07/17
JPMS
12/07/17
NO CHANGE
JPMS
Overweight
Roche to outperform on 'very strong' lung cancer data, says JPMorgan
JPMorgan analyst Richard Vosser says Roche reported "very strong" detailed progression free survival data from its IMPower150 lung cancer study. At the conference later today, the analyst expects to see strong interim overall survival data. He expects the shares to outperform by 1%-2% following this morning's data. Vosser has an Overweight rating on Roche.
12/07/17
PIPR
12/07/17
NO CHANGE
PIPR
Roche lung cancer data underwhelming versus Merck's, says Piper Jaffray
Piper Jaffray analyst Richard Purkiss says that while Roche's (RHHBY) IMpower150 data are strong and suggesting a likelihood that the combination of Tecentriq with Avastin and chemo will be approved in non-small cell lung cancer, the data also appear underwhelming compared to Merck's (MRK) KN-21G trial data. The analyst does expect Tecentriq approval in lung cancer next year and reiterates an Overweight rating on Roche. Whether KN-021G represents the "high water mark" for efficacy can only be answered following full presentation of the remaining pivotal Phase 3 trials in this setting, and until then confusion is likely to remain, Purkiss tells investors in a research note. Merck in premarket trading is up 85c to $55.20 while Roche is down 93c to $30.40.

TODAY'S FREE FLY STORIES

MET

MetLife

$53.56

-0.29 (-0.54%)

12:31
01/23/18
01/23
12:31
01/23/18
12:31
Hot Stocks
MetLife issues statement on court decision to dismiss appeal in SIFI litigation »

MetLife chairman,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

  • 12

    Jun

CVE

Cenovus Energy

$10.43

0.04 (0.38%)

12:30
01/23/18
01/23
12:30
01/23/18
12:30
Options
Call buyers in Cenovus Energy as shares tick higher »

Call buyers in Cenovus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UTX

United Technologies

$135.52

0.31 (0.23%)

12:28
01/23/18
01/23
12:28
01/23/18
12:28
Technical Analysis
Technical Earnings Preview: United Technologies in uptrend before news »

The shares have been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

AGN

Allergan

$187.32

-0.83 (-0.44%)

12:25
01/23/18
01/23
12:25
01/23/18
12:25
Options
Allergan call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 06

    Feb

  • 16

    Feb

  • 25

    Mar

12:25
01/23/18
01/23
12:25
01/23/18
12:25
Conference/Events
Leerink healthcare services analysts hold an analyst/industry conference call »

Healthcare Services…

VZ

Verizon

$53.23

-0.235 (-0.44%)

12:22
01/23/18
01/23
12:22
01/23/18
12:22
Periodicals
Verizon giving employees 50 shares of restricted stock, CNBC reports »

CNBC's David Faber…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Jan

CHFN

Charter Financial

$18.13

-0.12 (-0.66%)

12:21
01/23/18
01/23
12:21
01/23/18
12:21
Hot Stocks
Charter Financial raises quarterly dividend to 8c per share from 5c »

Charter Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOX

21st Century Fox

$36.96

0.7 (1.93%)

, FOXA

21st Century Fox

$37.31

0.66 (1.80%)

12:20
01/23/18
01/23
12:20
01/23/18
12:20
Hot Stocks
21st Century Fox 'welcomes' part of CMA finding, 'disappointed' about plurality »

21st Century Fox (FOXA)…

FOX

21st Century Fox

$36.96

0.7 (1.93%)

FOXA

21st Century Fox

$37.31

0.66 (1.80%)

SKYAY

Sky

$55.97

0.72 (1.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

  • 07

    Feb

$NSD

NASDAQ Market Internals

12:17
01/23/18
01/23
12:17
01/23/18
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$227.58

7.12 (3.23%)

, AMZN

Amazon.com

$1,327.31

32.73 (2.53%)

12:16
01/23/18
01/23
12:16
01/23/18
12:16
Hot Stocks
Netflix's 'Mudbound' gets four Oscar noms, Amazon's 'The Big Sick' gets nod »

Films produced by Netflix…

NFLX

Netflix

$227.58

7.12 (3.23%)

AMZN

Amazon.com

$1,327.31

32.73 (2.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

  • 01

    Feb

  • 18

    Mar

$NYE

NYSE Market Internals

12:16
01/23/18
01/23
12:16
01/23/18
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPE

HP Enterprise

$16.46

0.41 (2.55%)

12:15
01/23/18
01/23
12:15
01/23/18
12:15
Options
Hewlett Packard Enterprise put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

NFLX

Netflix

$227.58

7.12 (3.23%)

, TRV

Travelers

$145.27

5.92 (4.25%)

12:10
01/23/18
01/23
12:10
01/23/18
12:10
General news
On The Fly: Top stock stories at midday »

Stocks opened little…

NFLX

Netflix

$227.58

7.12 (3.23%)

TRV

Travelers

$145.27

5.92 (4.25%)

VZ

Verizon

$53.31

-0.15 (-0.28%)

JNJ

Johnson & Johnson

$143.58

-4.565 (-3.08%)

PG

Procter & Gamble

$89.11

-2.78 (-3.03%)

TSLA

Tesla

$351.56

1.54 (0.44%)

RMD

ResMed

$103.82

16.306 (18.63%)

WHR

Whirlpool

$171.12

4.47 (2.68%)

TWTR

Twitter

$22.96

-0.36 (-1.54%)

INSM

Insmed

$30.86

1.58 (5.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 25

    Jan

  • 25

    Jan

  • 30

    Jan

  • 07

    Feb

  • 08

    Feb

  • 16

    Feb

  • 28

    Feb

  • 08

    Mar

UAL

United Continental

$76.96

0.09 (0.12%)

12:07
01/23/18
01/23
12:07
01/23/18
12:07
Technical Analysis
Technical Earnings Preview: United Continental has a potential bullish pattern »

Heading into earnings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 21

    Mar

RHHBY

Roche

$30.79

0.1 (0.33%)

12:05
01/23/18
01/23
12:05
01/23/18
12:05
Hot Stocks
Roche subsidiary treatment of gastric cancer granted FDA orphan status »

Genentech, a subsidiary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

  • 23

    Feb

SQ

Square

$44.69

-0.6 (-1.32%)

12:05
01/23/18
01/23
12:05
01/23/18
12:05
Options
Square call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jan

ATVI

Activision Blizzard

$71.30

0.73 (1.03%)

12:04
01/23/18
01/23
12:04
01/23/18
12:04
Recommendations
Activision Blizzard analyst commentary  »

Cowen sees 'some…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Feb

MDCO

The Medicines Co.

$28.81

3.98 (16.03%)

12:04
01/23/18
01/23
12:04
01/23/18
12:04
Hot Stocks
The Medicines Co. treatment of HoFH granted FDA orphan designation »

The FDA granted orphan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

TRNC

tronc

$21.00

1.47 (7.53%)

12:01
01/23/18
01/23
12:01
01/23/18
12:01
Periodicals
Tronc in talks for news partnership with Axios, WSJ says »

Los Angeles Times owner…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

CREE

Cree

$36.69

0.4 (1.10%)

11:59
01/23/18
01/23
11:59
01/23/18
11:59
Technical Analysis
Technical Earnings Preview: Cree has a potential bearish pattern »

Ahead of earnings news,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

ARNA

Arena Pharmaceuticals

$35.89

0.29 (0.81%)

11:58
01/23/18
01/23
11:58
01/23/18
11:58
Conference/Events
Arena Pharmaceuticals to hold Key Opinion Leader Event »

Key Opinion Leader…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ULTA

Ulta Beauty

$235.01

-9.12 (-3.74%)

11:57
01/23/18
01/23
11:57
01/23/18
11:57
Recommendations
Ulta Beauty analyst commentary  »

Ulta Beauty coupon likely…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCG

Scana

$43.80

0.44 (1.01%)

11:55
01/23/18
01/23
11:55
01/23/18
11:55
Options
SCANA put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:55
01/23/18
01/23
11:55
01/23/18
11:55
General news
Fed board nominee Goodfriend said the Fed was on the right path »

Fed board nominee…

11:50
01/23/18
01/23
11:50
01/23/18
11:50
General news
Treasury's $35 B 4-week bill sale was well received »

Treasury's $35 B…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.